Endothelial Gata5 transcription factor regulates blood pressure

Nature Communications

Volumn 6, Issue , 2015, Pages

  Messaoudi, Smail ^a   He, Ying ^a   Gutsol, Alex ^a   Wight, Andrew ^a   Hébert, Richard L ^a   Vilmundarson, Ragnar O ^b   Makrigiannis, Andrew P ^a   Chalmers, John ^c   Hamet, Pavel ^d   Tremblay, Johanne ^b   McPherson, Ruth ^b   Stewart, Alexandre F R ^b   Touyz, Rhian M ^e   Nemer, Mona ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; CD45 ANTIGEN; CHLORIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROCHLOROTHIAZIDE; INTERLEUKIN 6; NEPHRIN; NITRIC OXIDE; PODOCIN; POTASSIUM; PROTEIN KINASE B; RENIN; SHORT HAIRPIN RNA; SODIUM; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TRANSCRIPTION FACTOR GATA 5; GATA5 PROTEIN, HUMAN; GATA5 PROTEIN, MOUSE;

BLOOD; CELLS AND CELL COMPONENTS; ETIOLOGY; GENE EXPRESSION; GENETIC VARIATION; HOMINID; HYPERTENSION; NITRIC OXIDE; PHENOTYPE; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DERMAL MICROVASCULAR ENDOTHELIAL CELL; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXON; FEMALE; FLOW CYTOMETRY; FOCAL GLOMERULOSCLEROSIS; GENE INACTIVATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GLOMERULUS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; LEUKOCYTE; MALE; MESANGIUM CELL; MESENTERIC ARTERY; MOUSE; NEPHRON; NONHUMAN; PHENOTYPE; PLASMA RENIN ACTIVITY; POLYMERASE CHAIN REACTION; PROTEINURIA; QUANTITATIVE ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; UPREGULATION; URINARY EXCRETION; ANIMAL; BLOOD PRESSURE; C57BL MOUSE; DISEASE MODEL; ENDOTHELIUM CELL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY;

ANIMALIA; MUS;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; GATA5 TRANSCRIPTION FACTOR; HUMANS; HYPERTENSION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT;

EID: 84948809067     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9835     Document Type: Article

References (64)

1. Kearney, P. M. et al. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223 (2005).
2. Mancia, G. et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28, 1462-1536 (2007).
3. Perkovic, V., Huxley, R., Wu, Y., Prabhakaran, D. & MacMahon, S. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 50, 991-997 (2007).
4. Padmanabhan, S., Newton-Cheh, C. & Dominiczak, A. F. Genetic basis of blood pressure and hypertension. Trends Genet. 28, 397-408 (2012).
5. International Consortium for Blood Pressure Genome-Wide Association StudiesEhret, G. B. et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478, 103-109 (2011).
6. Kathiresan, S. & Srivastava, D. Genetics of human cardiovascular disease. Cell 148, 1242-1257 (2012).
7. Bonachea, E. M. et al. Rare GATA5 sequence variants identified in individuals with bicuspid aortic valve. Pediatr. Res. 76, 211-216 (2014).
8. Padang, R., Bagnall, R. D., Richmond, D. R., Bannon, P. G. & Semsarian, C. Rare non-synonymous variations in the transcriptional activation domains of GATA5 in bicuspid aortic valve disease. J. Mol. Cell. Cardiol. 53, 277-281 (2012).
9. Laforest, B., Andelfinger, G. & Nemer, M. Loss of Gata5 in mice leads to bicuspid aortic valve. J. Clin. Invest. 121, 2876-2887 (2011).
10. Pikkarainen, S., Tokola, H., Kerkela, R. & Ruskoaho, H. GATA transcription factors in the developing and adult heart. Cardiovasc. Res. 63, 196-207 (2004).
11. Morrisey, E. E., Ip, H. S., Tang, Z., Lu, M. M. & Parmacek, M. S. GATA-5: a transcriptional activator expressed in a novel temporally and spatially-restricted pattern during embryonic development. Dev. Biol. 183, 21-36 (1997).
12. Nemer, G. & Nemer, M. Transcriptional activation of BMP-4 and regulation of mammalian organogenesis by GATA-4 and -6. Dev. Biol. 254, 131-148 (2003).
13. Nemer, G. & Nemer, M. Cooperative interaction between GATA5 and NF-ATc regulates endothelial-endocardial differentiation of cardiogenic cells. Development 129, 4045-4055 (2002).
14. van Berlo, J. H., Maillet, M. & Molkentin, J. D. Signaling effectors underlying pathologic growth and remodeling of the heart. J. Clin. Invest. 123, 37-45 (2013).
15. Cuspidi, C. et al. Prevalence of electrocardiographic left ventricular hypertrophy in human hypertension: an updated review. J. Hypertens. 30, 2066-2073 (2012).
16. James, P. A. et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507-520 (2014).
17. Ellison, D. H. & Loffing, J. Thiazide effects and adverse effects: insights from molecular genetics. Hypertension 54, 196-202 (2009).
18. Coffman, T. M. Under pressure: the search for the essential mechanisms of hypertension. Nat. Med. 17, 1402-1409 (2011).
19. De Miguel, C., Das, S., Lund, H. & Mattson, D. L. T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1136-R1142 (2010).
20. Fleming, I. Molecular mechanisms underlying the activation of eNOS. Pflugers Arch. 459, 793-806 (2010).
21. Abeyrathna, P. & Su, Y. The critical role of Akt in cardiovascular function. Vascul. Pharmacol. doi: 10.1016/j.vph.2015.05.008 (2015).
22. Drummond, G. R., Selemidis, S., Griendling, K. K. & Sobey, C. G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug Discov. 10, 453-471 (2011).
23. Dandona, S. et al. Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J. Am. Coll. Cardiol. 56, 479-486 (2010).
24. Patel, A. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370, 829-840 (2007).
25. Desmet, F. O. et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 37, e67 (2009).
26. Taddei, S. et al. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 94, 1298-1303 (1996).
27. Schlaich, M. P. et al. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation 110, 3680-3686 (2004).
28. Giannotti, G. et al. Impaired endothelial repair capacity of early endothelial progenitor cells in prehypertension: relation to endothelial dysfunction. Hypertension 55, 1389-1397 (2010).
29. Dananberg, J., Sider, R. S. & Grekin, R. J. Sustained hypertension induced by orally administered nitro-L-arginine. Hypertension 21, 359-363 (1993).
30. Huang, P. L. et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377, 239-242 (1995).
31. Yang, Q. et al. AVE3085, an enhancer of endothelial nitric oxide synthase, restores endothelial function and reduces blood pressure in spontaneously hypertensive rats. Br. J. Pharmacol. 163, 1078-1085 (2011).
32. Shiojima, I. & Walsh, K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 90, 1243-1250 (2002).
33. Boo, Y. C. et al. Shear stress stimulates phosphorylation of endothelial nitricoxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A. J. Biol. Chem. 277, 3388-3396 (2002).
34. Kou, R. & Michel, T. Epinephrine regulation of the endothelial nitric-oxide synthase: roles of RAC1 and beta3-adrenergic receptors in endothelial NO signaling. J. Biol. Chem. 282, 32719-32729 (2007).
35. Chen, Z. et al. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ. Res. 104, 496-505 (2009).
36. Bungard, D. et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 329, 1201-1205 (2010).
37. Wang, S. et al. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ. Res. 106, 1117-1128 (2010).
38. Gongol, B. et al. AMPK alpha2 exerts its anti-inflammatory effects through PARP-1 and Bcl-6. Proc. Natl Acad. Sci. USA 110, 3161-3166 (2013).
39. Miriyala, S. et al. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation. Circulation 113, 2818-2825 (2006).
40. Csiszar, A., Labinskyy, N., Jo, H., Ballabh, P. & Ungvari, Z. Differential proinflammatory and prooxidant effects of bone morphogenetic protein-4 in coronary and pulmonary arterial endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 295, H569-H577 (2008).
41. Tang, Y., Harrington, A., Yang, X., Friesel, R. E. & Liaw, L. The contribution of the Tie2 lineage to primitive and definitive hematopoietic cells. Genesis 48, 563-567 (2010).
42. Heng, T. S. & Painter, M. W.Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091-1094 (2008).
43. Hall, J. E. et al. Hypertension: physiology and pathophysiology. Compr. Physiol. 2, 2393-2442 (2012).
44. Wang, W. et al. Endothelial nitric oxide synthase-deficient mice exhibit increased susceptibility to endotoxin-induced acute renal failure. Am. J. Physiol. Renal. Physiol. 287, F1044-F1048 (2004).
45. Mennuni, S. et al. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J. Hum. Hypertens. 28, 74-79 (2014).
46. Holterman, C. E. et al. Nephropathy and elevated BP in mice with podocytespecific NADPH oxidase 5 expression. J. Am. Soc. Nephrol. 25, 784-797 (2014).
47. Jefferson, J. A. & Shankland, S. J. The pathogenesis of focal segmental glomerulosclerosis. Adv. Chronic Kidney Dis. 21, 408-416 (2014).
48. Daehn, I. et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. J. Clin. Invest. 124, 1608-1621 (2014).
49. Tominaga, T. et al. Activation of bone morphogenetic protein 4 signaling leads to glomerulosclerosis that mimics diabetic nephropathy. J. Biol. Chem. 286, 20109-20116 (2011).
50. Trott, D. W. & Harrison, D. G. The immune system in hypertension. Adv. Physiol. Educ. 38, 20-24 (2014).
51. Helmer, O. M. & Judson, W. E. Metabolic studies on hypertensive patients with suppressed plasma renin activity not due to hyperaldosternosm. Circulation 38, 965-976 (1968).
52. Williams, S. F., Nicholas, S. B., Vaziri, N. D. & Norris, K. C. African Americans, hypertension and the renin angiotensin system. World J. Cardiol. 6, 878-889 (2014).
53. Lopez, M. J. et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 378, 65-68 (1995).
54. John, S. W. et al. Genetic decreases in atrial natriuretic peptide and saltsensitive hypertension. Science 267, 679-681 (1995).
55. Levy, D. et al. Genome-wide association study of blood pressure and hypertension. Nat. Genet. 41, 677-687 (2009).
56. Kato, N. et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat. Genet. 43, 531-538 (2011).
57. Cooper, D. N. Functional intronic polymorphisms: Buried treasure awaiting discovery within our genes. Hum. Genomics 4, 284-288 (2010).
58. Wang, L. et al. A functional intronic variant in the tyrosine hydroxylase (TH) gene confers risk of essential hypertension in the Northern Chinese Han population. Clin. Sci. 115, 151-158 (2008).
59. Sauna, Z. E. & Kimchi-Sarfaty, C. Understanding the contribution of synonymous mutations to human disease. Nat. Rev. Genet. 12, 683-691 (2011).
60. Davies, R. W. et al. Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ. Cardiovasc.Genet. 3, 468-474 (2010).
61. Takemoto, M. et al. A new method for large scale isolation of kidney glomeruli from mice. Am. J. Pathol. 161, 799-805 (2002).
62. Lautrette, A. et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat. Med. 11, 867-874 (2005).
63. Vandesompele, J. et al. Accurate normalization of real-time quantitative RTPCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034 (2002).
64. van der Leeuw, J. et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension 65, 115-121 (2015).